{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:17:58Z","timestamp":1759940278792},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"suining central hospital","award":["2021y11"],"award-info":[{"award-number":["2021y11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dermatomyositis is a rare idiopathic inflammatory disease with diverse presentations that can have varying degrees of cutaneous and systemic involvement. This phenotypic heterogeneity makes DM a therapeutic challenge. Some therapeutic drugs, such as hormones and immunosuppressants, have poor therapeutic effects. In recent years, tofacitinib has been reported to be effective in the treatment of dermatomyositis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of anti-MDA5 antibody-positive dermatomyositis that was relieved after treatment with tofacitinib, during which gallbladder gangrene and suppurative cholecystitis occurred. After cholecystectomy, we continued to use tofacitinib and achieved a good therapeutic effect.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Tofacitinib is effective in the treatment of anti-MDA5 antibody-positive dermatomyositis, but the risk of infection is increased. It can still be used after infection control. Close follow-up should be performed during the use of tofacitinib.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00693-0","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T06:16:04Z","timestamp":1652595364000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib"],"prefix":"10.1186","volume":"27","author":[{"given":"Man","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"693_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","volume":"100","author":"S Wendel","year":"2019","unstructured":"Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib\u2014a report of two cases. J Autoimmun. 2019;100:131\u20136.","journal-title":"J Autoimmun"},{"key":"693_CR2","doi-asserted-by":"publisher","first-page":"108451","DOI":"10.1016\/j.clim.2020.108451","volume":"215","author":"A Takatani","year":"2020","unstructured":"Takatani A, Koga T, Fujita Y, et al. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis. Clinic Immunol. 2020;215:108451.","journal-title":"Clinic Immunol"},{"issue":"6","key":"693_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","volume":"58","author":"MK Siamak","year":"2019","unstructured":"Siamak MK, Devon C, Rohit A, et al. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford). 2019;58(6):1011\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"693_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"H You","year":"2020","unstructured":"You H, Xu D, Zhao J, et al. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol. 2020;59(3):334\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"693_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","volume":"14","author":"IE Lundberg","year":"2018","unstructured":"Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14(5):269\u201378.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"693_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","volume":"21","author":"GA Cobos","year":"2020","unstructured":"Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339\u201353.","journal-title":"Am J Clin Dermatol"},{"key":"693_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with Anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12: 773352.","journal-title":"Front Immunol"},{"issue":"9865","key":"693_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour-necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451\u201360.","journal-title":"Lancet"},{"issue":"6","key":"693_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495\u2013507.","journal-title":"N Engl J Med"},{"issue":"11","key":"693_CR10","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"693_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJM194910272411703","volume":"241","author":"WJ Clifford","year":"1949","unstructured":"Clifford WJ. Acute gangrenous cholecystitis. N Engl J Med. 1949;241(17):640\u20133.","journal-title":"N Engl J Med"},{"issue":"22","key":"693_CR12","doi-asserted-by":"publisher","first-page":"e26238","DOI":"10.1097\/MD.0000000000026238","volume":"100","author":"J Lee","year":"2021","unstructured":"Lee J, Lee YJ, Kim Y. Acute acalculous cholecystitis as the initial manifestation of systemic lupus erythematous: a case report. Medicine. 2021;100(22):e26238.","journal-title":"Medicine"},{"issue":"1","key":"693_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus-kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71\u201387.","journal-title":"Ann Rheum Dis"},{"key":"693_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.695768","volume":"12","author":"KJ Zhu","year":"2021","unstructured":"Zhu KJ, Yang PD, Xu Q. Tofacitinib treatment of refractory cutaneous leukocytoclastic vasculitis: a case report. Front Immunol. 2021;12: 695768.","journal-title":"Front Immunol"},{"issue":"9","key":"693_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/annrheumdis-2021-220049","volume":"80","author":"O Melikhov","year":"2020","unstructured":"Melikhov O, Kruglova T, Lytkina K. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals. Ann Rheum Dis. 2020;80(9):1245\u20136.","journal-title":"Ann Rheum Dis"},{"key":"693_CR16","doi-asserted-by":"publisher","DOI":"10.7326\/ACPJ202110190-111","author":"SYC Tong","year":"2021","unstructured":"Tong SYC, Petersiel N. Tofacitinib reduced death or respiratory failure at 28d in patients hospitalized with COVID-19 pneumonia. Ann Intern Med. 2021. https:\/\/doi.org\/10.7326\/ACPJ202110190-111.","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00693-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00693-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00693-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T06:23:05Z","timestamp":1652595785000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00693-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00693-0","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]},"assertion":[{"value":"7 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The case report was approved and supervised by the ethics committee of the Suining Central Hospital. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}